CTKB
Cytek Biosciences IncNASDAQHEALTHCAREMEDICAL DEVICES
Key Statistics
Market Cap
$593.90M
P/E Ratio
—
EPS
$-0.52
Beta
1.28
52W High
$6.18
52W Low
$2.37
50-Day MA
$4.50
200-Day MA
$4.33
Dividend Yield
—
Profit Margin
-33.00%
Forward P/E
370.37
PEG Ratio
—
About Cytek Biosciences Inc
Cytek Biosciences Inc (CTKB) is a pioneering force in multi-parameter flow cytometry, providing state-of-the-art cell analysis solutions to the life sciences industry. The company's advanced technologies facilitate comprehensive cellular analyses that are crucial for research in immunology, cancer diagnostics, and drug development. With a commitment to innovation and excellence in customer service, Cytek has solidified its status as a key contributor in the biotechnology sector, addressing the growing need for precise cell analysis tools. Boasting a diverse product portfolio and a robust market position, the company continues to drive advancements in the rapidly evolving field of cell biology research.
Fundamentals
| Revenue (TTM) | $201.49M |
| Gross Profit (TTM) | $104.46M |
| EBITDA | $-32.80M |
| Operating Margin | -9.00% |
| Return on Equity | -18.00% |
| Return on Assets | -5.25% |
| Revenue/Share (TTM) | $1.58 |
| Book Value | $2.66 |
| Price-to-Book | 1.71 |
| Price-to-Sales (TTM) | 2.95 |
| EV/Revenue | 1.716 |
| EV/EBITDA | 222.69 |
| Quarterly Earnings Growth (YoY) | 73.50% |
| Quarterly Revenue Growth (YoY) | 8.10% |
| Shares Outstanding | $128.55M |
| Float | $103.56M |
| % Insiders | 8.41% |
| % Institutions | 64.86% |
Historical Volatility
HV 10-Day
37.33%
HV 20-Day
41.18%
HV 30-Day
38.52%
HV 60-Day
43.72%
HV Rank
2.0%
Volatility is currently contracting
Analyst Ratings
Consensus ($6.00 target)
1
Strong Buy1
Buy3
HoldData last updated: 4/10/2026